Pfizer advances pneumonia shot after getting positive results in children

Pfizer Inc. said a new version of its bestselling Prevnar vaccine may provide infants with better protection against common ...

Pfizer begins late-stage trial for new pneumococcal shot in infants after strong phase 2 data

Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...

Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE)

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

Pfizer Advances Pneumonia Vaccine After 15-Fold Antibody Response Data

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.
The Caledonian-Record

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent ...
USA Today

Lyme disease vaccine shows strong results. How it works.

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

Pfizer didn't say hantavirus is side effect of its COVID-19 vaccine, contrary to online claims

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.